Postswitching discontinuation of biosimilars in psoriasis: registry analyses fall short in addressing real-world biases
- PMID: 39761694
- DOI: 10.1093/bjd/ljaf003
Postswitching discontinuation of biosimilars in psoriasis: registry analyses fall short in addressing real-world biases
Conflict of interest statement
Conflicts of interest: L.P. has perceived consultancy/speaker’s honoraria from and/or participated in clinical trials sponsored by AbbVie, Almirall, Amgen, Biogen, Boehringer Ingelheim, Bristol Myers Squibb, Fresenius-Kabi, Horizon, J&J Innovative Medicine, LEO Pharma, Lilly, Novartis, Pfizer, Samsung-Bioepis, STADA, Sun Pharma and UCB.
Comment on
-
Drug survival and safety of biosimilars for treating psoriasis compared with originator adalimumab: a multinational cohort study.Br J Dermatol. 2025 Mar 18;192(4):641-652. doi: 10.1093/bjd/ljae454. Br J Dermatol. 2025. PMID: 39565180
Publication types
LinkOut - more resources
Full Text Sources